Elephantiasis (Lymphatic Filariasis) Pipeline Review, H1 2019 Edition - ResearchAndMarkets.com

DUBLIN--()--The "Elephantiasis (Lymphatic Filariasis) - Pipeline Review, H1 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.

Elephantiasis (Lymphatic Filariasis) - Pipeline Review, H1 2019, provides comprehensive information on the therapeutics under development for Elephantiasis (Lymphatic Filariasis) (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Elephantiasis (Lymphatic Filariasis) (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Elephantiasis (Lymphatic Filariasis) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I and Preclinical stages are 1, 2 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively.

Elephantiasis (Lymphatic Filariasis) (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Elephantiasis (Lymphatic Filariasis) (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Elephantiasis (Lymphatic Filariasis) (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Elephantiasis (Lymphatic Filariasis) (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Elephantiasis (Lymphatic Filariasis) (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Elephantiasis (Lymphatic Filariasis) (Infectious Disease)

Key Topics Covered:

  1. Introduction
  2. Report Coverage
  3. Elephantiasis (Lymphatic Filariasis) - Overview
  4. Elephantiasis (Lymphatic Filariasis) - Therapeutics Development
  5. Pipeline Overview
  6. Pipeline by Companies
  7. Pipeline by Universities/Institutes
  8. Products under Development by Companies
  9. Products under Development by Universities/Institutes
  10. Elephantiasis (Lymphatic Filariasis) - Therapeutics Assessment
  11. Assessment by Route of Administration
  12. Assessment by Molecule Type
  13. Elephantiasis (Lymphatic Filariasis) - Companies Involved in Therapeutics Development
  • AbbVie Inc
  • Eisai Co Ltd
  • Medicines Development Ltd

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/pmi214

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900